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ABSTRACT
Head and neck squamous cell carcinomas (HNSCC) contain a small subpopulation of stem cells
endowed with unique capacity to generate tumors. These cancer stem cells (CSC) are localized in
perivascular niches and rely on crosstalk with endothelial cells for survival and self-renewal, but
the mechanisms involved are unknown. Here, we report that stromal interleukin (IL)26 deﬁnes
the tumorigenic capacity of CSC sorted from primary human HNSCC and transplanted into mice.
In search for the cellular source of Interleukin-6 (IL-6), we observed a direct correlation between
IL-6 levels in tumor-associated endothelial cells and the tumorigenicity of CSC. In vitro, endothe-
lial cell-IL-6 enhanced orosphere formation, p-STAT3 activation, survival, and self-renewal of
human CSC. Notably, a humanized anti-IL-6R antibody (tocilizumab) inhibited primary human
CSC-mediated tumor initiation. Collectively, these data demonstrate that endothelial cell-secreted
IL-6 deﬁnes the tumorigenic potential of CSC, and suggest that HNSCC patients might beneﬁt
from therapeutic inhibition of IL-6/IL-6R signaling. STEM CELLS 2014;32:2845–2857
INTRODUCTION
Head and neck squamous cell carcinomas
(HNSCC) contain a small population of highly
tumorigenic cells that exhibit self-renewal and
multipotency, hallmarks of stem cells [1, 2].
Emerging evidence from HNSCC and other
tumor types suggests that cancer stem cells
(CSC) exhibit resistance to chemotherapy and
radiotherapy and might be involved in the
establishment of metastasis, which is a major
cause of cancer-related deaths [3–5]. Such
ﬁndings led to the hypothesis that improve-
ments in the long-term outcome of patients
with cancer will require ablation of CSC. CSC
and physiological stem cells share similar char-
acteristics, such as differentiation and self-
renewal [6, 7]. Therefore, direct targeting of
CSC might be accompanied by toxicities related
to the unintended elimination of normal stem
cells (e.g., hematopoietic stem cells). We
recently demonstrated that CSC reside in peri-
vascular niches in patients with HNSCC, and that
endothelial cells contribute to the survival and
self-renewal of CSC [8]. Importantly, CSC depend
on crosstalk with tumor-associated endothelial
cells for their survival and maintenance of an
undifferentiated state [8], which may also con-
tribute to tumor dormancy [9]. These discoveries
raise the exciting possibility that cancer patients
may beneﬁt from the therapeutic blockade of
the crosstalk between endothelial cells and CSC
within the perivascular niche.
Both, physiological and CSC, depend on their
microenvironment for survival and proliferation
[6, 7, 10]. The protective function of the crosstalk
among cells within the perivascular niche has
been identiﬁed in neural stem cells [11] and neu-
ral tumors [12]. The observation that CSC reside in
perivascular niches in HNSCC [8] suggests that
potent antiangiogenic drugs may have a therapeu-
tic effect on both, the endothelial cells and the
CSC. However, emerging evidence demonstrated
that certain antiangiogenic therapies might lead
to the development of evasive resistance by
enhancing the invasive phenotype of tumor cells
[13–15]. These studies suggest that patients may
beneﬁt from a targeted approach that blocks
signaling pathways initiated by endothelial cells
and that contribute to CSC survival and self-
renewal. However, the mechanisms involving
the crosstalk between endothelial cells and CSC
are unknown, leaving these targets unidentiﬁed.
Independent studies have shown a strong
correlation between high serum Interleukin-6
(IL-6) levels and poor survival of patients with
head and neck cancer [16, 17]. These studies
have proposed the use of serum IL-6 as a bio-
marker to predict tumor recurrence and
patient survival. IL-6 activates its downstream
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CANCER STEM CELLS
target signal transducer and activator of transcription 3
(STAT3), which is constitutively active in several malignancies
including those of the head and neck [18]. Indeed, therapeu-
tic inhibition of STAT3 has been found to slow down tumor
growth [19, 20]. Interestingly, IL-6 plays a critical role in the
biology of CSC in breast and brain tumors [21–23]. It is known
that endothelial cells secrete high levels of IL-6, especially in
response to inﬂammatory stimuli [24], which play a major
role in the pathobiology of most epithelial cancers. It has also
been shown that the IL-6 receptors (IL-6R, gp130) exhibit
aberrant expression patterns in some CSC, such as gliomas
[22]. However, the role of IL-6 signaling in the crosstalk
between endothelial cells and CSC remains unknown.
Here, we unveiled a paracrine signaling pathway initiated
by IL-6 secreted by endothelial cells that enhances the survival,
self-renewal, and tumorigenic potential of primary human head
and neck cancer stem-like cells. Using laser capture microdis-
section (LCM), we determined that IL-6 expression is higher in
the endothelial cells than in the tumor cells of primary human
HNSCC, providing strong clinical rationale for this study. Nota-
bly, we observed that endothelial cell-secreted IL-6 enhances
the tumorigenic potential and the survival of cancer stem-like
cells using a series of complementary approaches that included
transplantation of primary human head and neck cancer stem-
like cells (ALDHHIGHCD44HIGH) into athymic IL-62/2 mice, gen-
eration of xenograft tumors with ALDHHIGHCD44HIGH cells that
are vascularized with human endothelial cells stably transduced
with shRNA-IL-6, and treatment of mice bearing tumors gener-
ated with ALDHHIGHCD44HIGH cells with an anti-IL-6R antibody
(tocilizumab). Collectively, these data demonstrate that endo-
thelial IL-6 contributes to the biology of CSC and suggest that
therapeutic inhibition of this pathway would be beneﬁcial for
patients with head and neck cancer.
MATERIALS AND METHODS
Head and Neck Cancer Stem-Like Cell Sorting
The use of primary human tumor specimens was done under
protocols approved by the University of Michigan Institutional
Review Board. Tumors were cut and minced with a sterile
scalpel until they could pass through a 25 ml pipette tip. They
were mixed in a 9:1 solution of Dulbecco’s modiﬁed Eagle’s
medium (DMEM)-F-12 (Hyclone, Waltham, MA. www.thermo-
scientiﬁc.com) and Collagenase/Hyaluronidase (Stem Cell Tech-
nologies, Vancouver, BC, Canada. www.stemcell.com). This
mixture was then incubated at 37C for 1 hour and passed
through a 10-ml pipette every 15 minutes for mechanical disso-
ciation. Cells were ﬁltered through a 40-mm nylon sieve (BD
Falcon, BD Biosciences, Franklin Lakes, NJ. www.bdbiosciences.
com), washed with low glucose DMEM, and centrifuged at
800 rpm for 3 minutes. Single-cell suspensions obtained from pri-
mary specimens (as well as from cell lines or xenografts) were
washed, counted, and resuspended at 1 3 106 cells per milliliter
PBS. The Aldeﬂuor kit (Stem Cell Technologies, Vancouver, BC,
Canada.) was used to identify cells with high ALDH activity.
Brieﬂy, cells were suspended in activated Aldeﬂuor substrate
BODIPY-aminoacetate (BAA) or in a speciﬁc ALDH inhibitor diethy-
laminobenzaldehyde (DEAB) for 45 minutes at 37C. Then, cells
were exposed to anti-CD44 (clone G44-26BD; Pharmingen, BD
Biosciences, Franklin Lakes, NJ). A series of lineage markers
(i.e., anti-CD2, CD3, CD10, CD16, CD18, and CD31; BD Pharmin-
gen) was used to eliminate lineage cells, mouse cells were elimi-
nated using anti-H2Kd antibody (BD Biosciences, Franklin Lakes,
NJ. www.bdbiosciences.com), and 7-Aminoactinomycin (BD Phar-
mingen) was used to eliminate nonviable cells. Here and through-
out this manuscript, in vitro studies were done in at least
triplicate specimens per condition, and three independent experi-
ments were performed to verify reproducibility of the data.
Orosphere Assay
Nonadherent spheroids of head and neck cancer cells (named
orospheres) were generated from ﬂuorescence-activated cell-
sorted cells (53 103 cells/well) cultured in triplicate wells in
ultra-low attachment plates (Corning, NY. www.corning.com), as
we showed [25]. Brieﬂy, cells were cultured in low glucose
DMEM containing or not 24-hour conditioned medium (CM)
from primary human dermal microvascular endothelial cells
(HDMEC, Lonza, Indianapolis, Indiana. www.lonza.com) collected
in serum-free endothelial basal medium (Lonza) at a ratio of 3:1.
Alternatively, cells were treated with HDMEC CM containing
0.4 mg/ml anti-IL-6 antibody (R&D Systems, Minneapolis, MN.
www.rndsystems.com), 10 mg/ml humanized anti-IL-6R antibody
(Tocilizumab, Chugai Pharmaceuticals, Tokyo, Japan. www.
chugai-pharm.co.jp), or nonspeciﬁc isotype-matched IgG. As a
positive control, we used 20 ng/ml rhIL-6 (R&D Systems). After
3 days, orospheres (deﬁned as colonies of 25 cells) were
visualized and quantiﬁed under light microscopy.
Severe Combined Immunodeficient Mouse Model of
Human Tumor Angiogenesis
Xenograft tumors vascularized with functional human micro-
vessels were generated in severe combined immunodeﬁcient
(SCID) mice (CB17 SCID; Taconic, Hudson, NY. www.taconic.com),
as we described [26]. Brieﬂy, 0–1,000 head and neck cancer
stem-like cells (ALDHHIGHCD44HIGH) or 1,000 non-CSC (ALDHLOW
CD44LOW) were seeded along with 5 3 105 HDMEC-shRNA-IL-6
or HDMEC-shRNA-C in poly(L-lactic) acid biodegradable scaffolds.
Bilateral scaffolds were implanted subcutaneously in the dorsum
of each mouse. Alternatively, mice received scaffolds con-
taining 5 3 105 HDMEC cells and 1 3 103 ALDHHIGHCD44HIGH or
ALDHLOWCD44LOW cells. Starting on Day 1, mice received weekly
intraperitoneal injections of either 10 mg/kg humanized anti-IL-
6R antibody (Chugai Pharmaceuticals) or nonspeciﬁc IgG, as
described [27]. After 30 days, mice were euthanized and tumors
were retrieved, measured, weighed, and processed. The impact
of host IL-6 on tumor initiation was evaluated in C57B6 IL-62/2
and IL-61/1 mice [28] originally purchased from the Jackson
Laboratories, and backcrossed onto an immunodeﬁcient/athymic
mouse background.
RESULTS
Stromal IL-6 Enhances the Survival of Cancer
Stem-Like Cells
Serum IL-6 has been identiﬁed as an independent predictor of
poor survival in head and neck squamous cell carcinoma
patients [17]. It is known that IL-6 is a potent inﬂammatory
cytokine secreted by stromal cells, and that IL-6 enhances
stem cell properties in gliomas [22]. However, the mecha-
nisms underlying the effect of endothelial cell-secreted IL-6
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on the biology of HNSCC are unknown. To begin to under-
stand the impact of stromal IL-6 on the survival of CSC, we
generated tumor xenografts by transplanting primary human
cancer stem-like cells in IL-62/2 athymic mice (Fig. 1A). For
this, immediately after surgical removal of the primary tumor
from patients with HNSCC (Supporting Information Fig. S1),
cancer stem-like cells (i.e., ALDHHIGHCD44HIGH) were sorted
and transplanted in the IL-61/1 mice. 1,000 ALDHHIGHCD44-
HIGH cells transplanted in the IL-61/1 mice generated more
and larger tumors than transplantation of 1,000 ALDH-
HIGHCD44HIGH into IL-62/2 deﬁcient littermates (Fig. 1B).
Importantly, the fraction of ALDHHIGHCD44HIGH cells in the
tumor xenografts generated in the IL-62/2 mice was approxi-
mately 10-fold smaller than the fraction of ALDHHIGHCD44HIGH
cells in control mice (p5 .001) (Fig. 1C). These data
demonstrate that stromal IL-6 plays a critical role in the head
and neck tumor microenvironment, and contributes CSC sur-
vival, tumor initiation, and growth.
Considering our recent observation that CSC reside in the
perivascular niche in HNSCC [8], and the demonstration that
endothelial cells challenged by mediators of inﬂammation
secrete high levels of IL-6 [24], we explored the possibility
that tumor-associated endothelial cells constitute an impor-
tant source of IL-6 within the perivascular CSC niche. To
quantify the relative expression of IL-6 in different microenvir-
onmental compartments in human HNSCC, we performed
Figure 1. Stromal IL-6 supports the survival of cancer stem-like cells. (A): Schematic representation of the approach used for testing
the role of stromal IL-6 on the tumorigenic potential of cancer stem-like cells (ALDHHIGHCD44HIGH) in primary tumors. ALDHHIGHCD44HIGH
cells were isolated from primary human HNSCC and implanted in IL-62/2 or IL-61/1 immunodeﬁcient mice. At the termination of the
experiment, tumors were retrieved, single-cell suspensions prepared, and the proportion of ALDHHIGHCD44HIGH cells determined by
FACS. (B): Graph represents the volume of tumors arising from primary human ALDHHIGHCD44HIGH cells transplanted into IL-62/2 or IL-
61/1 immunodeﬁcient mice. (C): Graph depicting the percentage of cancer stem-like cells in tumor xenografts, as compared to the pri-
mary tumor. (D): RT-PCR showing the mRNA expression of IL-6 in human endothelial cells as compared to the tumor cells. Cells were
retrieved by LCM from parafﬁn-embedded sections from four different patients with primary HNSCC. (E): Confocal microscopy of a pri-
mary human HNSCC immunostained for ALDH1 (green) and IL-6R (red). DAPI (blue) identiﬁed nuclei (Patient 19). (F): Western Blot for
IL-6R and gp130 in head and neck cancer stem-like cells (ALDHHIGHCD44HIGH) and control cells (ALDHLOWCD44LOW) sorted from two
HNSCC cell lines (UM-SCC-74A, UM-SCC-74B). Abbreviations: FACS, ﬂuorescence-activated cell sorting; HNSCC, head and neck squamous
cell carcinomas; IL-6, interleukin-6; LCM, laser capture microdissection.
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LCM of endothelial cells or carcinoma cells from several head
and neck cancer patients [29] and observed that IL-6 expres-
sion was signiﬁcantly higher in the endothelial cells than in
the tumor cells (Fig. 1D). These data were corroborated by
the observation that human endothelial cells secrete more IL-
6 than HNSCC cell lines (p< .05) (Supporting Information Fig.
S2A, S2B). Confocal microscopy from human HNSCC tissue
sections revealed colocalization of ALDH and IL-6R (Fig. 1E).
Western blots showed that ALDHHIGHCD44HIGH cells express
higher levels of IL-6R than control ALDHLOWCD44LOW cells,
while the expression of gp130 was similar (Fig. 1F). Collec-
tively, these data demonstrated that the elements required
for an IL-6-mediated crosstalk within the perivascular stem
cell niche are in place in human head and neck tumors.
Endothelial Cell-Secreted IL-6 Enhances the Survival of
Cancer Stem-Like Cells and Promotes Tumor Initiation
To evaluate the impact of endothelial cell-secreted IL-6 on the
biology of cancer stem-like cells, we silenced its expression in
primary human dermal microvascular endothelial cells
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(HDMEC) and used these cells to generate tumor xenografts
with a humanized vasculature, as we described [26]. In an
attempt to verify the speciﬁcity of lentiviral-mediated IL-6
silencing in primary endothelial cells, we observed a signiﬁ-
cant inhibition of IL-6 expression, but no signiﬁcant change in
expression of IL-8 (Supporting Information Fig. S2C). Using
this approach, we have shown that the vast majority of the
blood vessels within the xenograft tumors are lined with the
human endothelial cells that were transplanted in the scaffold
[26]. We observed that xenograft tumors vascularized with IL-
6-silenced endothelial cells exhibited similar microvessel den-
sity as those vascularized with endothelial cells transduced
with empty lentiviral vectors (p5 .117). The tumor cells used
here were primary human cancer stem-like (ALDHHIGHCD44-
HIGH) cells sorted from three different patients with HNSCC
(Fig. 2A–2D). Time to palpability was used as a determinant
of the tumorigenic potential of the cell combinations tested
here. We observed that transplantation of 1,000 ALDH-
HIGHCD44HIGH cells generated tumors in 100% of the mice
(n5 26) within 38 days (Fig. 2B). However, cotransplantation
of HDMEC-shRNA-IL-6 with ALDHHIGHCD44HIGH signiﬁcantly
delayed (p5 .0016) the time to tumor palpability as com-
pared to cotransplantation of scrambled sequence control
endothelial cells and ALDHHIGHCD44HIGH (Fig. 2B). When indi-
vidual tumors are tracked, one observes an overall trend for
earlier initiation and larger volumes of tumors vascularized
with HDMEC-shRNA-C than in tumors vascularized with
HDMEC-shRNA-IL-6 cells (Fig. 2C). Notably, the average vol-
ume was smaller when endothelial cells stably transduced
with shRNA-IL-6 were used to vascularize the xenograft
tumors generated with cancer stem-like cells sorted from
three different patients, demonstrating that this effect was
not patient-speciﬁc (Fig. 2D).
To more rigorously study the effect of endothelial cell-
secreted IL-6 on tumor initiation, we performed a serial dilu-
tion experiment. We implanted 1,000, 100, 10, or 0 ALDH-
HIGHCD44HIGH cells sorted from a primary human HNSCC along
with either HDMEC-shRNA-C or HDMEC-shRNA-IL-6 cells. We
observed that cotransplantation of HDMEC-shRNA-IL-6 with
ALDHHIGHCD44HIGH signiﬁcantly delayed (p5 .0004) tumor ini-
tiation as compared to cotransplantation of control endothe-
lial cells and ALDHHIGHCD44HIGH (Fig. 2E), conﬁrming the data
discussed above (Fig. 2B). Notably, all implants containing at
least 10 ALDHHIGHCD44HIGH cells generated tumors (Fig. 2F).
However, the larger the number of cancer stem-like cells, the
shorter the time to palpability (Fig. 2F). A pair-wise statistical
comparison between different ALDHHIGHCD44HIGH cell densities
demonstrated that the greater the initial number of cancer
stem-like cells, the greater the effect of endothelial cell-
secreted IL-6 in promoting tumors (Fig. 2G). Together, these
studies demonstrate that endothelial cell-secreted IL-6 enhan-
ces the tumorigenic potential of cancer stem-like cells in vivo.
The density (fraction) of CSC in a tumor is considered
indicative of poor prognosis for cancer patients [30]. To evalu-
ate the effects of endothelial cell-secreted IL-6 on the fraction
of cancer stem-like cells in vivo, we evaluated the percentage
of ALDHHIGHCD44HIGH cells in xenograft tumors generated with
cancer stem-like cells retrieved from primary human HNSCC
(Fig. 2A). Ablation of endothelial cell-secreted IL-6 within the
tumor microenvironment resulted in a signiﬁcant decrease in
the proportion of cancer stem-like cells (p5 .041), as com-
pared to xenografts vascularized with control endothelial cells
from cancer stem-like cells from primary patients (Fig. 3A). To
conﬁrm the studies performed with cells sorted from primary
human HNSCC, we repeated these analyses with cells sorted
from a well-characterized human HNSCC cell line (UM-SCC-
74A). We observed that the fraction of cancer stem-like cells
was signiﬁcantly reduced (p5 .010) and the tumor initiation
in xenografts was delayed (p5 .0008) when xenografts were
vascularized with IL-6-silenced human endothelial cells (Fig.
3B, 3C). Notably, the tumor microvascular density was not
affected by the silencing of IL-6 in the endothelial cells, as
determined by sorting these xenograft tumors for the endo-
thelial marker CD31 (Supporting Information Fig. S2D).
Endothelial Cell-Secreted IL-6 Promotes CSC
Properties In Vitro
To evaluate the functional role of endothelial cell-secreted IL-
6 on cancer stem-like cells in vitro, we exposed unsorted
head and neck cancer cells (UM-SCC-74A) to endothelial cell
CM in presence of a neutralizing antibody to IL-6 and meas-
ured the percentage of ALDHHIGHCD44HIGH by ﬂow cytometry
(Fig. 3D). Endothelial cell CM increased the fraction of cancer
stem-like cells (Fig. 3D, 3E). However, treatment of the CM
with anti-IL-6 antibody reduced the percentage of cancer
stem-like cells back to baseline levels (Fig. 3E), without a sig-
niﬁcant effect in overall cell survival (data not shown). To
evaluate the effect of endothelial cell-secreted IL-6 on the
Figure 2. Endothelial cell-secreted IL-6 enhances the tumorigenic potential of cancer stem-like cells. (A): Schematic representation of
the approach used for testing the role of endothelial cell-secreted IL-6 on the tumorigenic potential of primary human ALDHHIGHCD44-
HIGH cells. ALDHHIGHCD44HIGH cells were sorted from primary HNSCC and implanted in immunodeﬁcient mice to generate xenograft
tumors vascularized with HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C. (B): Graph showing the percentage of palpable tumors over
time in ALDHHIGHCD44HIGH tumors vascularized with HDMEC-shRNA-IL-6 or HDMEC-shRNA-C. (C): Graph showing individual tumor vol-
ume over time (n5 13). Photomicrographs (3200) of HE-stained tissue sections of scaffolds containing 1,000 primary human ALDH-
HIGHCD44HIGH cells and vascularized with HDMEC-shRNA-IL-6 or HDMEC-shRNA-C, 30 days after implantation in severe combined
immunodeﬁcient mice. Few (if any) tumor cells are visible in the implants vascularized with HDMEC-shRNA-IL-6, while the entire micros-
copy ﬁeld is populated with tumor cells in the implants vascularized with HDMEC-shRNA-C. The PLLA scaffold (white areas) is still visible
in the implants containing ALDHHIGHCD44HIGH/HDMEC-shRNA-IL-6, while in the ALDHHIGHCD44HIGH/HDMEC-shRNA-C group the scaffold
has already been completely resorbed by the enzymatic activity of the tumor cells. (D): Graph showing the average tumor volume of
tumor xenografts generated by cells sorted from HNSCC from three patients at Day 45 (p< .05). (E–G): ALDHHIGHCD44HIGH cells were
isolated from a primary HNSCC (Patient 26) and implanted in serial dilutions of 1,000, 100, 10, or 0 cells along with 500,000 HDMEC-
shRNA-IL-6 or HDMEC-shRNA-C cells in immunodeﬁcient mice. (E): Graph showing the overall trend for time to palpability. In this case,
the zero ALDHHIGHCD44HIGH cell group was not included, as no tumors were observed in this experimental condition. (F): Graph showing
the percentage of palpable tumors over time for each individual experimental condition. (G): Table showing the pairwise statistics for
the experimental conditions that generated tumors, as determined using the Bonferroni correction at p< .0125. Abbreviations: HDMEC,
human dermal microvascular endothelial cells; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
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survival and self-renewal of cancer cells, we plated
ALDHHIGHCD44HIGH or ALDHLOWCD44LOW cells in ultra-low
attachment plates and evaluated the formation of nonadher-
ent colonies of cells (named orospheres). As expected, more
orospheres were generated by ALDHHIGHCD44HIGH cells than
from ALDHLOWCD44LOW cells, and the number of orospheres
was increased upon treatment with endothelial cell CM (Fig.
3F; Supporting Information Fig. S3), conﬁrming our previous
report [8]. Notably, neutralizing anti-IL-6 antibody inhibited
the inductive effect of endothelial cell CM, while rhIL-6
increased the number of orospheres (but not to the same
extent as the CM). To ascertain that the orospheres were not
formed simply by cell aggregation, we also performed single-
cell colony formation assays in ultra-low attachment plates
(Fig. 3G). We observed that endothelial cell CM increased the
number of orospheres as compared to controls, and that an
anti-IL-6 neutralizing antibody blocked this effect.
To verify the data obtained with anti-IL-6 antibody, we
used a second approach consisted of treating unsorted tumor
cells with CM from the HDMEC-shRNA-IL-6 or HDMEC-C cells
2850 Endothelial IL-6 and Cancer Stem Cells
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(Fig. 3H). A more potent induction of the CSC fraction upon
treatment with CM from HDMEC-shRNA-C than with HDMEC-
shRNA-IL-6 CM was observed (Fig. 3H, 3I). Importantly, silenc-
ing of IL-6 in the endothelial cells abrogated endothelial cell
CM-induced orosphere formation (Fig. 3J). And adding
recombinant human IL-6 was sufﬁcient to rescue the effect of
IL-6-depleted conditioned-media on orosphere formation (Fig.
3J).
It has been postulated that CSC exhibit an invasive pheno-
type, which could be involved in the generation of secondary
tumors [31]. Considering the fact that human HNSCC are
highly invasive, we evaluated the effects of endothelial cell-
secreted IL-6 on the invasive phenotype of ALDHHIGHCD44HIGH
cells in vitro. We observed that CM from endothelial cells sig-
niﬁcantly enhanced the invasive potential of ALDHHIGHCD44-
HIGH cells (Supporting Information Fig. S4A, S4B). Notably,
treatment with neutralizing antibody against IL-6, or exposure
to HDMEC-shRNA-IL-6 CM, abrogated the inductive effect of
the endothelial cell CM (Supporting Information Fig. S4).
Taken together, these ﬁndings demonstrate that endothelial
cells constitute a critical source of the IL-6 that promotes the
survival, self-renewal, and invasive potential of head and neck
cancer stem-like cells in vitro.
Endothelial Cell-Secreted IL-6 Induces STAT3
Phosphorylation in CSC
The canonical IL-6 signal transduction pathway involves bind-
ing to IL-6R and to the common signal transducing receptor
gp130, signaling through the Janus kinases, and activation of
STAT3. Activation of STAT3 signaling plays an important role in
the self-renewal and stemness of embryonic stem cells, intes-
tinal stem cells, and glioblastoma stem cells [23, 32–34].
Therefore, phosphorylation of STAT3 might be considered
indicative of stemness. Immunohistochemical examination of
primary HNSCC tissues showed strong expression of p-STAT3
around tumor blood vessels (Fig. 4A), where most human
HNSCC cancer stem-like cells are located. To evaluate the
expression pattern of p-STAT3 in cancer stem-like cells, we
sorted cells from a primary HNSCC and observed that ALDH-
HIGHCD44HIGH cells exhibit constitutive phosphorylation of
STAT3 while the non-stem cell population (ALDHLOWCD44LOW)
did not (Fig. 4B). It is known that the activation of the ERK-
MAPK pathway correlates with the loss of stemness and
acquisition of a more differentiated state [35, 36]. Here, we
observed that cancer stem-like cells (ALDHHIGHCD44HIGH)
showed low expression of p-ERK, while ALDHLOWCD44LOW cells
exhibited constitutive activation of this pathway (Fig. 4B). Par-
allel experiments with a head and neck cancer cell line (UM-
SCC-74A) also conﬁrmed there was signiﬁcant expression of P-
STAT3 with cells sorted from primary HNSCC (Fig. 4B).
To evaluate the impact of endothelial cell-secreted factors
on the activation of STAT3, we exposed ALDHHIGHCD44HIGH cells
to endothelial cell CM and analyzed the phosphorylation levels
of STAT3 over time. We found that endothelial cell CM
enhanced STAT3 phosphorylation in ALDHHIGHCD44HIGH cells in
a time-dependent manner (Fig. 4C). Blockade of IL-6 with neu-
tralizing antibodies abrogated the inductive effect of endothe-
lial cells on STAT3 phosphorylation (Fig. 4D). Likewise, exposure
of cancer stem-like cells to CM from IL-6-silenced endothelial
cells did not induce STAT3 phosphorylation beyond baseline
levels (Fig. 4E). Notably, knockdown STAT3 in ALDHHIGHCD44-
HIGH cells (Fig. 4F) prevented rhIL-6-induced increase in the
number of orospheres (Fig. 4I). And silencing of IL-6R (Fig. 4F)
inhibited baseline levels of STAT3 phosphorylation, and par-
tially inhibited endothelial cell CM-induced P-STAT3 (Fig. 4G).
The number of orospheres induced by endothelial cell CM was
also smaller in IL-6R-silenced tumor cells, as compared to con-
trols (Fig. 4H). Collectively, these data demonstrated that IL-6
secreted by endothelial cells signals through IL-6R to activate
STAT3 signaling, which functions as a critical regulator of the
self-renewal and survival of head and neck CSC.
Humanized Anti-IL-6R Antibody Inhibits the Survival of
Cancer Stem-Like Cells and Delays Tumor Initiation
To enhance the translational signiﬁcance of this work, we per-
formed a series of experiments with the humanized anti-
human IL-6R antibody tocilizumab developed by Chugai/Roche
[27]. This antibody was approved by the FDA for the treat-
ment of rheumatoid arthritis in 2010. Tocilizumab blocked the
effect of endothelial cell CM on the generation of orospheres
with cells sorted from primary HNSCC (Fig. 5A) and inhibited
endothelial cell-induced phosphorylation of STAT3 in vitro
(Fig. 5B). To test the efﬁcacy of inhibition of IL-6R signaling on
tumor initiation, we implanted ALDHHIGHCD44HIGH or ALDH-
LOWCD44LOW cells sorted from a primary HNSCC and treated
the mice with tocilizumab (or IgG controls) for 4 weeks
Figure 3. Endothelial cell-secreted IL-6 promotes the survival and self-renewal of cancer stem-like cells. (A): ALDHHIGHCD44HIGH cells
were isolated from a primary human HNSCC (Patient 22) and transplanted into severe combined immunodeﬁcient mice along with
HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C. Tumors were retrieved after 30 days. Graph showing the percentage of ALDHHIGHCD44-
HIGH cells as determined by ﬂuorescence-activated cell sorting (FACS), p5 .041. (B): ALDHHIGHCD44HIGH cells were isolated from a HNSCC
cell line (UM-SCC-74A) and transplanted into immunodeﬁcient mice along with HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C. Graph
showing the percentage of ALDHHIGHCD44HIGH cells after 30 days, as determined by FACS, p5 .010. (C): Graph showing the percentage
of palpable tumors over time (n5 6), p5 .0008. (D): Representative FACS analysis of UM-SCC-74A cells treated with endothelial cell CM
with or without neutralizing antibody against IL-6 for 48 hours. Number in the top right quadrant depicts the percentage of ALDH-
HIGHCD44HIGH cells in the sample. (E): Graph depicting the quantiﬁcation and statistical analyses of the specimens showed in panel D.
(F): Graph depicting the number of orospheres arising from ALDHHIGHCD44HIGH and ALDHLOWCD44LOW cells cultured under ultra-low
attachment conditions and treated with CM from endothelial cells (HDMEC) in presence of anti-IL-6 neutralizing antibody or IgG control.
(G): Graph depicting the number of orospheres arising from ALDHHIGHCD44HIGH cells sorted from UM-SCC-74A, cultured in 96-well ultra-
low attachment plates and treated with CM from endothelial cells (HDMEC) in presence of anti-IL-6 antibody or IgG. In this case, one
cell was seeded per well, to eliminate the possibility of cell aggregation. (H): Representative FACS analysis of UM-SCC-74A cells treated
with CM from HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C for 48 hours and (I) is the quantiﬁcation and statistical analysis of these
data. (J): Graph depicting the number of orospheres arising from ALDHHIGHCD44HIGH cells (UM-SCC-74A) cultured in ultra-low attachment
plates and treated with CM from HDMEC-shRNA-C, HDMEC-shRNA-IL-61/2 20 ng/ml rhIL-6, or unconditioned medium. Different lower
case letters represent p< .05. Abbreviations: EC CM, endothelial cell conditioned medium; HDMEC, human dermal microvascular endo-
thelial cells; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
Krishnamurthy, Warner, Dong et al. 2851
www.StemCells.com VC AlphaMed Press 2014
Figure 4. Endothelial cell-secreted IL-6 activates the STAT3 pathway in head and neck cancer stem-like cells (A): Immunohistochemical
localization of ALDH1-positive and p-STAT3-positive cells in tumor xenografts generated with ALDHHIGHCD44HIGH cells sorted from primary
human HNSCC. (B): Western blot showing baseline phosphorylation of STAT3 and ERK in head and neck cancer stem-like cells (ALDH-
HIGHCD44HIGH) compared to control cells (ALDHLOWCD44LOW) sorted from a primary HNSCC (Patient 28) or from a head and neck cancer
cell line (UM-SCC-74A). (C): Western blot for phosphorylated and total STAT3 in ALDHHIGHCD44HIGH cells cultured in ultra-low attachment
plates and treated with endothelial cell CM for 0–24 hours. (D): Western blots for phosphorylated and total STAT3 in ALDHHIGHCD44HIGH or
ALDHLOWCD44LOW cells treated with endothelial cell CM in presence of anti-IL-6 antibody or IgG for 15 minutes. (E): Western blots for
phosphorylated and total STAT3 in ALDHHIGHCD44HIGH or ALDHLOWCD44LOW cells treated with CM collected from HDMEC-shRNA-IL-6 or con-
trol HDMEC-shRNA-C for 30 minutes. (F): Western blot to determine the effectiveness of IL-6R knockdown in UM-SCC-74A cells (shRNA-IL-
6R); and STAT3 knockdown in UM-SCC-74B cells (shRNA-STAT3). We used three different shRNA sequences and determined that sequence
(c) was the most effective to downregulate STAT3 expression. As controls, we transduced cells with a scrambled sequence (shRNA-C). (G):
Western blots for phosphorylated and total STAT3 in UM-SCC-74A cells transduced with shRNA-IL-6R (or control shRNA-C) and exposed to
endothelial cell conditioned medium for 0–60 minutes. (H): Graph depicting the number of orospheres arising from UM-SCC-74A cells sta-
bly transduced with shRNA-IL-6R or shRNA-C and cultured in ultra-low attachment plates. All cells were cultured in presence of 24-hour EC
CM. The untreated control for these experiments was serum-free endothelial basal (EBM) medium. (I): Graph depicting the number of oro-
spheres arising from UM-SCC-74B cells stably transduced with shRNA-STAT3(c) or shRNA-C and cultured in ultra-low attachment plates.
Cells were cultured in presence (or absence) of 20 ng/ml rhIL-6. The untreated control for this experiment was serum-free EBM supple-
mented with PBS (vehicle for rhIL-6). Different lower case letters represent p< .05. Abbreviations: EC CM, endothelial cell conditioned
medium; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
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Figure 5. A humanized anti-human IL-6R antibody (tocilizumab) inhibits self-renewal and tumor initiation of human head and neck can-
cer stem-like cells transplanted in mice. (A): Graph represents the relative number of orospheres arising from ALDHHIGHCD44HIGH and
ALDHLOWCD44LOW cells cultured in ultra-low attachment plates with endothelial cell CM in presence of 0 or 10 mg/ml anti-IL-6R anti-
body. (B): Western blot showing the phosphorylation of STAT3 in ALDHHIGHCD44HIGH and ALDHLOWCD44LOW cells cultured in ultra-low
attachment plates with endothelial cell CM in presence of 0 or 10 mg/ml anti-IL-6R antibody. (C): Schematic representation of the exper-
imental design. Tumor xenografts were generated by the implantation of 1,000 ALDHHIGHCD44HIGH or ALDHLOWCD44LOW cells sorted from
a primary human HNSCC (Patient 34) along with 5 3 105 primary endothelial cells (HDMEC). Mice received weekly intraperitoneal injec-
tions of 10 mg/kg anti-IL-6R antibody or IgG for 4 weeks. (D, E): Kaplan-Meier analysis showing the percentage of palpable tumors over
time (D). Palpable tumor is deﬁned as tissue overgrowth beyond the size of the scaffold used for cell transplantation. Tumors were only
observed upon transplantation of ALDHHIGHCD44HIGH cells, that is, six tumors out of six transplants in the IgG-treated group, and one
tumor out of six transplants in the IL-6R antibody-treated group. None of the scaffolds transplanted with ALDHLOWCD44LOW cells gener-
ated a tumor. (E): Graph showing the tumor volume 30 days after transplantation. Please note that the volume of the scaffold by itself
(without palpable tumor) measured through the skin is typically 70–100 mm3. (F): Graph showing the percentage of ALDHHIGHCD44HIGH
cells as determined by ﬂuorescence-activated cell sorting. These data are derived from the xenografts treated (or not) with the anti-IL-
6R antibody and compared to the percentage of ALDHHIGHCD44HIGH cells found in the primary human HNSCC. (G): Schematic representa-
tion of the experimental design. Tumor xenografts (n5 18) were generated by the implantation of ALDHHIGHCD44HIGH cells sorted from
UM-SCC-74B cells along with primary human endothelial cells (HDMEC). Mice received weekly intraperitoneal injections of 10 mg/kg
anti-IL-6R antibody or IgG for 16 weeks. Alternatively, treatment with anti-IL-6R antibody was stopped after 4 weeks and mice were fol-
lowed up for additional 12 weeks without treatment. (H): Graph depicting the percentage of ALDHHIGHCD44HIGH cells at the end of the
experimental period (16 weeks). Different lower case letters represent p< .05. Abbreviations: EC CM, endothelial cell conditioned
medium; HDMEC, human dermal microvascular endothelial cells; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
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(Fig. 5C). No signiﬁcant weight reduction was observed in mice
treated with tocilizumab during the course of this experiment,
suggesting that this drug was well tolerated (Supporting Infor-
mation Fig. S5). While all mice transplanted with 1,000 ALDH-
HIGHCD44HIGH cells developed tumors in the IgG control group
(6/6), only one tumor (1/6) was created in the tocilizumab
group (Fig. 5D). As expected, none of the mice (0/12) trans-
planted with control ALDHLOWCD44LOW cells developed tumors
within the experimental time (Fig. 5D). The average tumor vol-
ume of the mice in the IgG group was signiﬁcantly higher than
in the tocilizumab-treated group (Fig. 5E). Importantly, we
observed a signiﬁcant reduction in the proportion of CSC
(ALDHHIGHCD44HIGH cells) in mice treated with tocilizumab, as
compared to mice from the IgG control group (Fig. 5F).
To more fully understand the effect of the anti-IL-6R antibody
tocilizumab on the fraction of CSC, we performed a long-term in
vivo of 4 months (Fig. 5G). In this case, we generated xenograft
tumors with ALDHHIGHCD44HIGH cells sorted from UM-SCC-74B
and administered weekly anti-IL-6R antibody for 16 weeks or for
4 weeks followed by 12 weeks without antibody. We observed
that treatment with the anti-IL-6R antibody resulted in a smaller
fraction of ALDHHIGHCD44HIGH cells in this tumor model. Surpris-
ingly, this effect was maintained in the group without antibody
for the last 12 weeks, suggesting that the effect of IL-6 signaling
blockade on head and neck CSC is long lasting.
DISCUSSION
Acquired resistance to therapy is a major challenge in the man-
agement of patients with head and neck cancer. Platinum-
based drugs have substantially improved the control of local-
regional disease [37]. However, with improved local control of
the disease with enhanced radiation therapy, concurrent chem-
otherapy, and advanced surgical techniques, distant metastasis
has become a larger percentage of failures in patients with
oral cancer [38]. As a consequence, the survival of patients
with HNSCC remained largely unchanged over the last 35 years
[39]. The poor survival and high recurrence/metastasis rates in
patients with HNSCC can possibly be explained by the CSC
hypothesis where the regeneration of a tumor (or the estab-
lishment of metastatic foci) requires at least one CSC. Notably,
CSC are believed to be resistant to conventional chemothera-
peutic drugs, exhibit an invasive phenotype, and resist anoikis
or death by anchorage independence. These characteristics
make CSC prime candidates to drive the process of recurrence
and metastasis frequently observed in patients with head and
neck cancer. Here, we performed a series of complementary
studies to understand mechanisms used by primary human
head and neck CSC to survive while retaining an undifferenti-
ated and highly tumorigenic phenotype.
We have previously demonstrated that the combination of
high ALDH activity and high CD44 expression discriminates a
small subpopulation of highly tumorigenic cells that have the
features of CSC in HNSCC [8]. We found that these cells exist
in perivascular niches and that endothelial cell-secreted fac-
tors enhanced the survival of the CSC, but the critical media-
tors of this crosstalk were unclear. The importance of stromal
IL-6 on tumor initiation and tumor growth was demonstrated
in this study by experiments with xenografts generated with
stem-like cells sorted from primary human HNSCC and
implanted in immunodeﬁcient IL-62/2 or IL-61/1 mice.
We observed a 10-fold decrease in the proportion of cancer
stem-like cells in tumors generated in the IL-62/2 mice. These
results demonstrated that host-derived IL-6 plays an important
role in the survival/self-renewal of CSC. Ongoing studies attempt
to determine whether this effect was mediated by a direct inter-
action of the host IL-6 with the cancer stem-like cells, or indi-
rectly by modulating the inﬂammatory response. Here, our
focus was directed to the endothelial cells as a source of the
stromal IL-6 for the following reasons: (a) We observed that
endothelial cells express high IL-6 levels in human HNSCC; (b)
IL-6 is upregulated under inﬂammatory conditions [24], which
are typically observed in HNSCC; and (c) CSC exhibit perivascular
localization in the head and neck tumor microenvironment.
We observed that endothelial-secreted IL-6 enhances the
survival and the stem cell properties of head and neck cancer
cells. Interestingly, IL-6 is secreted from thymic blood vessels
in response to therapy and promotes the survival of
doxorubicin-resistant cells in Burkitt’s lymphoma [40]. One
could speculate that these resistant cells exhibit stem-like
properties. Furthermore, work in lung carcinomas recently
showed that stromal endothelial cells contribute to tumor
growth [41]. We observed here that IL-6 secreted by endothe-
lial cells is a potent inducer of the tumor-initiating capacity of
head and cancer stem-like cells. These data do not exclude
the possibility that other cell types (e.g., myeloid cells) con-
tribute to the overall levels of IL-6 in the tumor microenviron-
ment. However, the experiments in which complementary
xenograft tumor models are vascularized with IL-6-silenced
endothelial cells (or controls) provide strong evidence that IL-
6 secreted by the vascular endothelium is a key determinant
of the fraction of CSC and the time-to-palpability of tumors.
Taken together, these studies identify endothelial cell-initiated
signaling events as important mediators of the tumorigenicity
of CSC and suggest that such events may contribute to the
development of acquired resistance to therapy.
While the concept of perivascular niche for stem cells has
been described several years ago [11, 12], the understanding
of the complex cell-cell interactions within the niche is still
emerging. It is known that stem cells reside nearby blood ves-
sels in many tissues, including the bone marrow, brain, and
heart [42]. It is also known that endothelial cells in steady
state secrete IL-6, and that IL-6 expression can be upregulated
by inﬂammatory cytokines such as IL-1b [43]. These studies
suggest that endothelial cell-secreted IL-6 may play a role in
the maintenance of the stem cell pool within physiological
conditions, and perhaps also during inﬂammation. In
head and neck tumors, we observed that IL-6 secreted
by endothelial cells induces survival and self-renewal of
ALDHHIGHCD44HIGH cancer stem-like cells. Although we
observed an increase in the number of orospheres with rhIL-6
treatment, it was not as potent as the induction mediated by
complete endothelial cell CM. This suggests that other endo-
thelial cell-secreted factors might contribute to the biology
and behavior of CSC. For example, interleukin-8 (CXCL8) is a
chemokine that signals through CXCR1 and CXCR2, is
expressed in head and neck cancer, and has been implicated
in processes that regulate the biology of CSC [44–46]. We
have also recently observed that endothelial cell-secreted epi-
dermal growth factor induces epithelial to mesenchymal tran-
sition (EMT) in head and neck cancer cells, enhancing their
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migratory and invasive phenotype [47]. It is certainly possible
that complex signaling networks are activated by multiple cyto-
kines and chemokines secreted by endothelial cells, which would
explain the preferential localization of CSC in perivascular areas.
Our in vitro results demonstrated that the invasive
potential of head and neck CSC is enhanced by the growth
factor milieu secreted by endothelial cells in an IL-6-
dependent manner. Such ﬁndings suggest that IL-6 secreted
by endothelial cells could facilitate the initiation of the meta-
static spread by generating a chemotactic gradient that
attracts tumor cells toward blood vessels. In fact, a recent
study showed that targeting STAT3 with Cucurbitacin I inhib-
ited tumorigenicity and distant metastasis in head and neck
tumor models [20]. This suggests a role of IL-6/STAT3 signal-
ing in EMT of HNSCC, as seen in breast cancers [48]. Like-
wise, local secretion of IL-6 at sites of endothelial cell
inﬂammation or injury might facilitate the homing of circu-
lating tumor progenitor cells to speciﬁc sites or organs, and
contribute to the development of distant metastases.
Although the mechanisms underlying the effect of stem cells
on the biology of HNSCC are still unclear, our data suggest
that a crosstalk initiated by endothelial cells contributes to
the progression of head and neck tumors and that interfer-
ence with this crosstalk may constitute a viable conceptual
target for treatment of these tumors.
Collectively, the understanding of the physiological role of
IL-6 and the mechanistic studies performed here, provided the
rationale for the therapeutic targeting of the IL-6 signaling path-
way in HNSCC. It has been observed that the most common
adverse effects of therapeutic inhibition of IL-6R in clinical stud-
ies are respiratory tract infections, headaches, and hypertension
[49], which might be related to biological roles of endothelial
cell-derived IL-6 in the recruitment of immune cells and regula-
tion of vascular physiology. Furthermore, IL-6 inhibitors are cur-
rently being tested in clinical trials for cancer apart from their
use in chronic inﬂammatory conditions. For example, the anti-IL-
6 monoclonal antibody CNTO 328 (siltuximab) is in clinical trials
for refractory multiple myelomas and metastatic renal cell can-
cer [50, 51]. Blockade of IL-6R signaling with tocilizumab inhib-
ited xenograft tumor angiogenesis [27]. Here, we observed that
tocilizumab dramatically inhibited the tumor-initiating capacity
of primary human cancer stem-like cells. Notably, the fraction of
cancer stem-like cells was signiﬁcantly decreased in the mice
treated with tocilizumab suggesting that inhibition of IL-6R sig-
naling was sufﬁcient to reduce the survival and/or self-renewal
of head and neck cancer stem-like cells in vivo.
CONCLUSIONS
We have recently demonstrated that silencing of IL-6 in endo-
thelial cells is sufﬁcient to slowdown tumor growth in proof-
of-principle experiments using a cervical adenocarcinoma
model [52]. Here, we demonstrated that endothelial cell-
secreted-IL-6 signaling through IL-6R promotes self-renewal
and survival of human primary head and neck cancer stem-
like cells (Fig. 6). Blockade of this signaling pathway inhibited
tumor initiation and reduced the fraction of cancer stem-like
cells in existing tumors. This work establishes the crosstalk
between endothelial cells and putative CSC as a critical mech-
anism of tumor initiation, and singles out IL-6 as an important
signaling molecule in this process. Considering the fact that
endothelial cells are readily accessible to systemic therapies,
and the recent discovery of potent and speciﬁc inhibitors,
therapeutic targeting of the IL-6 signaling pathway is emerg-
ing as a promising therapeutic strategy for patients with head
and neck squamous cell carcinoma.
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